{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:52:32Z","timestamp":1777402352127,"version":"3.51.4"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Mentored Research Scholar Grant MRSG-15-063-01-TBG"],"award-info":[{"award-number":["Mentored Research Scholar Grant MRSG-15-063-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11886-019-1184-y","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T09:02:50Z","timestamp":1564563770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pheochromocytoma\/Paraganglioma: Is This a Genetic Disorder?"],"prefix":"10.1007","volume":"21","author":[{"given":"Lauren","family":"Fishbein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"1184_CR1","volume-title":"WHO classification of tumours: pathology and genetics of tumours of endocrine organs","author":"RVOR Lloyd","year":"2017","unstructured":"Lloyd RVOR, Kloppel G, Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. Lyon: IARC; 2017.","edition":"4"},{"issue":"2","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/jc.2009-1051","volume":"95","author":"H Bruynzeel","year":"2010","unstructured":"Bruynzeel H, Feelders RA, Groenland TH, van den Meiracker AH, van Eijck CH, Lange JF, et al. Risk factors for hemodynamic instability during surgery for pheochromocytoma. J Clin Endocrinol Metab. 2010;95(2):678\u201385. \n                      https:\/\/doi.org\/10.1210\/jc.2009-1051\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101\u201311. \n                      https:\/\/doi.org\/10.1038\/nrendo.2014.188\n                      \n                    .","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","volume":"20","author":"L Fishbein","year":"2013","unstructured":"Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol. 2013;20(5):1444\u201350. \n                      https:\/\/doi.org\/10.1245\/s10434-013-2942-5\n                      \n                    .","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0467","volume":"175","author":"M Fassnacht","year":"2016","unstructured":"Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1\u2013G34. \n                      https:\/\/doi.org\/10.1530\/EJE-16-0467\n                      \n                    .","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"1184_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.15.S1.1","volume":"15","author":"MA Zeiger","year":"2009","unstructured":"Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. The American Association of Clinical Endocrinologists and American Association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl 1):1\u201320. \n                      https:\/\/doi.org\/10.4158\/EP.15.S1.1\n                      \n                    .","journal-title":"Endocr Pract"},{"key":"1184_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1196\/annals.1353.005","volume":"1073","author":"DL Cohen","year":"2006","unstructured":"Cohen DL, Fraker D, Townsend RR. Lack of symptoms in patients with histologic evidence of pheochromocytoma: a diagnostic challenge. Ann N Y Acad Sci. 2006;1073:47\u201351. \n                      https:\/\/doi.org\/10.1196\/annals.1353.005\n                      \n                    .","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/EJE-09-0384","volume":"161","author":"R Kopetschke","year":"2009","unstructured":"Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355\u201361. \n                      https:\/\/doi.org\/10.1530\/EJE-09-0384\n                      \n                    .","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/eje.0.1410619","volume":"141","author":"M Mannelli","year":"1999","unstructured":"Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999;141(6):619\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1245\/s10434-014-3933-x","volume":"22","author":"H Wachtel","year":"2015","unstructured":"Wachtel H, Cerullo I, Bartlett EK, Roses RE, Cohen DL, Kelz RR, et al. Clinicopathologic characteristics of incidentally identified pheochromocytoma. Ann Surg Oncol. 2015;22(1):132\u20138. \n                      https:\/\/doi.org\/10.1245\/s10434-014-3933-x\n                      \n                    .","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"\u2022 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915\u201342. \n                      https:\/\/doi.org\/10.1210\/jc.2014-1498\n                      \n                    . The Endocrine Society guidelines for the evaluation and treatment of pheochromocytomas and paragangliomas.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","volume":"287","author":"JW Lenders","year":"2002","unstructured":"Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427\u201334.","journal-title":"JAMA"},{"issue":"5","key":"1184_CR13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1210\/jc.2008-2419","volume":"94","author":"M Mannelli","year":"2009","unstructured":"Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and\/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94(5):1541\u20137. \n                      https:\/\/doi.org\/10.1210\/jc.2008-2419\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","volume":"20","author":"N Burnichon","year":"2011","unstructured":"Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974\u201385. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddr324\n                      \n                    .","journal-title":"Hum Mol Genet"},{"key":"1184_CR15","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1038\/ncomms7044","volume":"6","author":"LJ Castro-Vega","year":"2015","unstructured":"Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044. \n                      https:\/\/doi.org\/10.1038\/ncomms7044\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"2","key":"1184_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"\u2022 Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181\u201393. \n                      https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001\n                      \n                    . The Cancer Genome Atlas (TCGA) paper on germline and somatic genetics of pheochromocytoma and paraganglioma using integrated genomic sequencing.","journal-title":"Cancer Cell"},{"issue":"1","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/path.4503","volume":"236","author":"A Flynn","year":"2015","unstructured":"Flynn A, Benn D, Clifton-Bligh R, Robinson B, Trainer AH, James P, et al. The genomic landscape of phaeochromocytoma. J Pathol. 2015;236(1):78\u201389. \n                      https:\/\/doi.org\/10.1002\/path.4503\n                      \n                    .","journal-title":"J Pathol"},{"issue":"1","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","volume":"17","author":"H Hampel","year":"2015","unstructured":"Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70\u201387. \n                      https:\/\/doi.org\/10.1038\/gim.2014.147\n                      \n                    .","journal-title":"Genet Med"},{"issue":"7","key":"1184_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(7):671\u201382. \n                      https:\/\/doi.org\/10.1038\/gim.2018.28\n                      \n                    .","journal-title":"Genet Med"},{"issue":"15","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"YS Yap","year":"2014","unstructured":"Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, et al. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014;5(15):5873\u201392. \n                      https:\/\/doi.org\/10.18632\/oncotarget.2194\n                      \n                    .","journal-title":"Oncotarget"},{"key":"1184_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cen.13163","volume":"86","author":"LM Gruber","year":"2016","unstructured":"Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF Jr, Bancos I. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol. 2016;86:141\u20139. \n                      https:\/\/doi.org\/10.1111\/cen.13163\n                      \n                    .","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1184_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00403-010-1090-z","volume":"303","author":"L Zinnamosca","year":"2011","unstructured":"Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Schina M, Cianci R, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res. 2011;303(5):317\u201325. \n                      https:\/\/doi.org\/10.1007\/s00403-010-1090-z\n                      \n                    .","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68171-2","volume":"162","author":"MM Walther","year":"1999","unstructured":"Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen\u2019s disease and pheochromocytomas. J Urol. 1999;162(5):1582\u20136.","journal-title":"J Urol"},{"issue":"25","key":"1184_CR24","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1056\/NEJMc066006","volume":"354","author":"B Bausch","year":"2006","unstructured":"Bausch B, Borozdin W, Neumann HP. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med. 2006;354(25):2729\u201331. \n                      https:\/\/doi.org\/10.1056\/NEJMc066006\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"3","key":"1184_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","volume":"57","author":"G Eisenhofer","year":"2011","unstructured":"Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411\u201320. \n                      https:\/\/doi.org\/10.1373\/clinchem.2010.153320\n                      \n                    .","journal-title":"Clin Chem"},{"issue":"12","key":"1184_CR26","first-page":"B4763","volume":"60","author":"ML Binderup","year":"2013","unstructured":"Binderup ML, Bisgaard ML, Harbud V, Moller HU, Gimsing S, Friis-Hansen L, et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J. 2013;60(12):B4763.","journal-title":"Dan Med J"},{"issue":"5574","key":"1184_CR27","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1126\/science.1073440","volume":"296","author":"JH Min","year":"2002","unstructured":"Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 2002;296(5574):1886\u20139. \n                      https:\/\/doi.org\/10.1126\/science.1073440\n                      \n                    .","journal-title":"Science"},{"key":"1184_CR28","unstructured":"VHL Alliance. The VHL handbook. 5th ed. Boston (MA): VHL Alliance. 2015."},{"issue":"5","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00268-005-0359-4","volume":"30","author":"KA Delman","year":"2006","unstructured":"Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006;30(5):665\u20139. \n                      https:\/\/doi.org\/10.1007\/s00268-005-0359-4\n                      \n                    .","journal-title":"World J Surg"},{"issue":"6","key":"1184_CR30","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1210\/jc.2009-0354","volume":"94","author":"CC Boedeker","year":"2009","unstructured":"Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2009;94(6):1938\u201344. \n                      https:\/\/doi.org\/10.1210\/jc.2009-0354\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1184_CR31","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1210\/jc.2009-1479","volume":"94","author":"J Gaal","year":"2009","unstructured":"Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, et al. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2009;94(11):4367\u201371. \n                      https:\/\/doi.org\/10.1210\/jc.2009-1479\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1184_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617\u201323. \n                      https:\/\/doi.org\/10.1038\/ejhg.2010.175\n                      \n                    .","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/humu.20385","volume":"28","author":"KR Ong","year":"2007","unstructured":"Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007;28(2):143\u20139. \n                      https:\/\/doi.org\/10.1002\/humu.20385\n                      \n                    .","journal-title":"Hum Mutat"},{"issue":"2","key":"1184_CR34","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/ERC-17-0325","volume":"25","author":"SA Wells Jr","year":"2018","unstructured":"Wells SA Jr. Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors. Endocr Relat Cancer. 2018;25(2):T1\u2013T13. \n                      https:\/\/doi.org\/10.1530\/ERC-17-0325\n                      \n                    .","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1184_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610. \n                      https:\/\/doi.org\/10.1089\/thy.2014.0335\n                      \n                    .","journal-title":"Thyroid"},{"issue":"6","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","volume":"15","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Qi XP, Walz MK, Maia AL, Sanso G, Peczkowska M, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014;15(6):648\u201355. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(14)70154-8\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"1","key":"1184_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385. \n                      https:\/\/doi.org\/10.1016\/j.ccr.2004.11.022\n                      \n                    .","journal-title":"Cancer Cell"},{"issue":"12","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326\u201338. \n                      https:\/\/doi.org\/10.1101\/gad.191056.112\n                      \n                    .","journal-title":"Genes Dev"},{"issue":"12","key":"1184_CR39","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","volume":"23","author":"SP Rednam","year":"2017","unstructured":"\u2022 Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(12):e68\u201375. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0547\n                      \n                     Expert recommendation guidelines for screening patients with hereditary paraganglioma-pheochromocytoma syndrome.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","volume":"19","author":"N Burnichon","year":"2010","unstructured":"Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011\u201320. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddq206\n                      \n                    .","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1184_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s004390051033","volume":"106","author":"B Parfait","year":"2000","unstructured":"Parfait B, Chretien D, Rotig A, Marsac C, Munnich A, Rustin P. Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome. Hum Genet. 2000;106(2):236\u201343.","journal-title":"Hum Genet"},{"issue":"9","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","volume":"3","author":"B Bausch","year":"2017","unstructured":"Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3(9):1204\u201312. \n                      https:\/\/doi.org\/10.1001\/jamaoncol.2017.0223\n                      \n                    .","journal-title":"JAMA Oncol"},{"issue":"2","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1210\/jc.2017-01762","volume":"103","author":"K van der Tuin","year":"2018","unstructured":"van der Tuin K, Mensenkamp AR, Tops CMJ, Corssmit EPM, Dinjens WN, van de Horst-Schrivers ANA, et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study. J Clin Endocrinol Metab. 2018;103(2):438\u201345. \n                      https:\/\/doi.org\/10.1210\/jc.2017-01762\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922\u20138. \n                      https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256\n                      \n                    .","journal-title":"JAMA Oncol"},{"issue":"1","key":"1184_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/jnnp.2005.067041","volume":"77","author":"R Horvath","year":"2006","unstructured":"Horvath R, Abicht A, Holinski-Feder E, Laner A, Gempel K, Prokisch H, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry. 2006;77(1):74\u20136. \n                      https:\/\/doi.org\/10.1136\/jnnp.2005.067041\n                      \n                    .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1184_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1086\/321282","volume":"69","author":"D Astuti","year":"2001","unstructured":"Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69(1):49\u201354. \n                      https:\/\/doi.org\/10.1086\/321282\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1184_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2796.2009.02111.x","volume":"266","author":"B Pasini","year":"2009","unstructured":"Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med. 2009;266(1):19\u201342. \n                      https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02111.x\n                      \n                    .","journal-title":"J Intern Med"},{"key":"1184_CR48","doi-asserted-by":"publisher","unstructured":"\u2022 Andrews KA, Ascher DB, Pires DEV, Barnes DR, Vialard L, Casey RT, et al. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. J Med Genet. 2018;55(6):384\u201394. \n                      https:\/\/doi.org\/10.1136\/jmedgenet-2017-105127\n                      \n                    . This is one of the largest studies with index and non-index patients evaluating penetrance of SDHx gene pathogenic variants.","DOI":"10.1136\/jmedgenet-2017-105127"},{"issue":"8","key":"1184_CR49","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","volume":"143","author":"I Jochmanova","year":"2017","unstructured":"Jochmanova I, Wolf KI, King KS, Nambuba J, Wesley R, Martucci V, et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol. 2017;143(8):1421\u201335. \n                      https:\/\/doi.org\/10.1007\/s00432-017-2397-3\n                      \n                    .","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"1184_CR50","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/cen.12074","volume":"78","author":"M Jafri","year":"2013","unstructured":"Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar AV, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol. 2013;78(6):898\u2013906. \n                      https:\/\/doi.org\/10.1111\/cen.12074\n                      \n                    .","journal-title":"Clin Endocrinol"},{"issue":"2","key":"1184_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EJE-17-0074","volume":"177","author":"ND Niemeijer","year":"2017","unstructured":"Niemeijer ND, Rijken JA, Eijkelenkamp K, van der Horst-Schrivers ANA, Kerstens MN, Tops CMJ, et al. The phenotype of SDHB germline mutation carriers: a nationwide study. Eur J Endocrinol. 2017;177(2):115\u201325. \n                      https:\/\/doi.org\/10.1530\/EJE-17-0074\n                      \n                    .","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1184_CR52","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jmedgenet-2012-101192","volume":"49","author":"LT van Hulsteijn","year":"2012","unstructured":"van Hulsteijn LT, Dekkers OM, Hes FJ, Smit JW, Corssmit EP. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012;49(12):768\u201376. \n                      https:\/\/doi.org\/10.1136\/jmedgenet-2012-101192\n                      \n                    .","journal-title":"J Med Genet"},{"issue":"5454","key":"1184_CR53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.287.5454.848","volume":"287","author":"BE Baysal","year":"2000","unstructured":"Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848\u201351.","journal-title":"Science"},{"issue":"5","key":"1184_CR54","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/jc.2008-0569","volume":"93","author":"HP Neumann","year":"2008","unstructured":"Neumann HP, Erlic Z. Maternal transmission of symptomatic disease with SDHD mutation: fact or fiction? J Clin Endocrinol Metab. 2008;93(5):1573\u20135. \n                      https:\/\/doi.org\/10.1210\/jc.2008-0569\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1184_CR55","doi-asserted-by":"publisher","first-page":"E2009","DOI":"10.1210\/jc.2011-1244","volume":"96","author":"PM Yeap","year":"2011","unstructured":"Yeap PM, Tobias ES, Mavraki E, Fletcher A, Bradshaw N, Freel EM, et al. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. J Clin Endocrinol Metab. 2011;96(12):E2009\u201313. \n                      https:\/\/doi.org\/10.1210\/jc.2011-1244\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"key":"1184_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12881-014-0111-8","volume":"15","author":"JP Bayley","year":"2014","unstructured":"Bayley JP, Oldenburg RA, Nuk J, Hoekstra AS, van der Meer CA, Korpershoek E, et al. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet. 2014;15:111. \n                      https:\/\/doi.org\/10.1186\/s12881-014-0111-8\n                      \n                    .","journal-title":"BMC Med Genet"},{"issue":"1","key":"1184_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/humu.21136","volume":"31","author":"CJ Ricketts","year":"2010","unstructured":"Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41\u201351. \n                      https:\/\/doi.org\/10.1002\/humu.21136\n                      \n                    .","journal-title":"Hum Mutat"},{"issue":"3","key":"1184_CR58","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/81551","volume":"26","author":"S Niemann","year":"2000","unstructured":"Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26(3):268\u201370. \n                      https:\/\/doi.org\/10.1038\/81551\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"8","key":"1184_CR59","doi-asserted-by":"publisher","first-page":"E1482","DOI":"10.1210\/jc.2013-3853","volume":"99","author":"T Else","year":"2014","unstructured":"Else T, Marvin ML, Everett JN, Gruber SB, Arts HA, Stoffel EM, et al. The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3). J Clin Endocrinol Metab. 2014;99(8):E1482\u20136. \n                      https:\/\/doi.org\/10.1210\/jc.2013-3853\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1184_CR60","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","volume":"11","author":"JP Bayley","year":"2010","unstructured":"Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11(4):366\u201372. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(10)70007-3\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"2","key":"1184_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/1078-0432.CCR-10-0420","volume":"17","author":"HP Kunst","year":"2011","unstructured":"Kunst HP, Rutten MH, de Monnink JP, Hoefsloot LH, Timmers HJ, Marres HA, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17(2):247\u201354. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0420\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1184_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ng.533","volume":"42","author":"Y Qin","year":"2010","unstructured":"Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42(3):229\u201333. \n                      https:\/\/doi.org\/10.1038\/ng.533\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"23","key":"1184_CR63","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1001\/jama.2010.1830","volume":"304","author":"L Yao","year":"2010","unstructured":"Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, et al. Spectrum and prevalence of FP\/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA. 2010;304(23):2611\u20139. \n                      https:\/\/doi.org\/10.1001\/jama.2010.1830\n                      \n                    .","journal-title":"JAMA"},{"issue":"9","key":"1184_CR64","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/hmg\/ddt638","volume":"23","author":"Y Qin","year":"2014","unstructured":"Qin Y, Deng Y, Ricketts CJ, Srikantan S, Wang E, Maher ER, et al. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet. 2014;23(9):2428\u201339. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddt638\n                      \n                    .","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1184_CR65","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","volume":"18","author":"N Burnichon","year":"2012","unstructured":"Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18(10):2828\u201337. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0160\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1184_CR66","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ng.861","volume":"43","author":"I Comino-Mendez","year":"2011","unstructured":"Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43(7):663\u20137. \n                      https:\/\/doi.org\/10.1038\/ng.861\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"10","key":"1184_CR67","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922\u201330. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1205119\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"11","key":"1184_CR68","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","volume":"22","author":"I Comino-Mendez","year":"2013","unstructured":"Comino-Mendez I, de Cubas AA, Bernal C, Alvarez-Escola C, Sanchez-Malo C, Ramirez-Tortosa CL, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013;22(11):2169\u201376. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddt069\n                      \n                    .","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1184_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","volume":"91","author":"FR Lorenzo","year":"2013","unstructured":"Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, et al. A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013;91(4):507\u201312. \n                      https:\/\/doi.org\/10.1007\/s00109-012-0967-z\n                      \n                    .","journal-title":"J Mol Med (Berl)"},{"issue":"13","key":"1184_CR70","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2012-10-460972","volume":"121","author":"C Yang","year":"2013","unstructured":"Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013;121(13):2563\u20136. \n                      https:\/\/doi.org\/10.1182\/blood-2012-10-460972\n                      \n                    .","journal-title":"Blood."},{"issue":"2","key":"1184_CR71","doi-asserted-by":"publisher","first-page":"E369","DOI":"10.1210\/jc.2013-2600","volume":"99","author":"A Buffet","year":"2014","unstructured":"Buffet A, Smati S, Mansuy L, Menara M, Lebras M, Heymann MF, et al. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2014;99(2):E369\u201373. \n                      https:\/\/doi.org\/10.1210\/jc.2013-2600\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1184_CR72","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IP Tomlinson","year":"2002","unstructured":"Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406\u201310. \n                      https:\/\/doi.org\/10.1038\/ng849\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"9","key":"1184_CR73","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","volume":"23","author":"LJ Castro-Vega","year":"2014","unstructured":"Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014;23(9):2440\u20136. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddt639\n                      \n                    .","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1184_CR74","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","volume":"99","author":"GR Clark","year":"2014","unstructured":"Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA, et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab. 2014;99(10):E2046\u201350. \n                      https:\/\/doi.org\/10.1210\/jc.2014-1659\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1184_CR75","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41436-018-0068-7","volume":"20","author":"B Calsina","year":"2018","unstructured":"Calsina B, Curras-Freixes M, Buffet A, Pons T, Contreras L, Leton R, et al. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genet Med. 2018;20(12):1652\u201362. \n                      https:\/\/doi.org\/10.1038\/s41436-018-0068-7\n                      \n                    .","journal-title":"Genet Med"},{"issue":"5","key":"1184_CR76","doi-asserted-by":"publisher","first-page":"djv053","DOI":"10.1093\/jnci\/djv053","volume":"107","author":"A Cascon","year":"2015","unstructured":"Cascon A, Comino-Mendez I, Curras-Freixes M, de Cubas AA, Contreras L, Richter S, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst. 2015;107(5):djv053. \n                      https:\/\/doi.org\/10.1093\/jnci\/djv053\n                      \n                    .","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1184_CR77","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","volume":"78","author":"A Buffet","year":"2018","unstructured":"Buffet A, Morin A, Castro-Vega LJ, Habarou F, Lussey-Lepoutre C, Letouze E, et al. Germline mutations in the mitochondrial 2-oxoglutarate\/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res. 2018;78(8):1914\u201322. \n                      https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2463\n                      \n                    .","journal-title":"Cancer Res"},{"issue":"20","key":"1184_CR78","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-16-2250","volume":"23","author":"L Remacha","year":"2017","unstructured":"Remacha L, Comino-Mendez I, Richter S, Contreras L, Curras-Freixes M, Pita G, et al. Targeted exome sequencing of Krebs cycle genes reveals candidate cancer-predisposing mutations in pheochromocytomas and paragangliomas. Clin Cancer Res. 2017;23(20):6315\u201324. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2250\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1184_CR79","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41436-018-0003-y","volume":"20","author":"L Remacha","year":"2018","unstructured":"Remacha L, Curras-Freixes M, Torres-Ruiz R, Schiavi F, Torres-Perez R, Calsina B, et al. Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genet Med. 2018;20(12):1644\u201351. \n                      https:\/\/doi.org\/10.1038\/s41436-018-0003-y\n                      \n                    .","journal-title":"Genet Med"},{"issue":"4","key":"1184_CR80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ajhg.2019.02.017","volume":"104","author":"L Remacha","year":"2019","unstructured":"Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Curras-Freixes M, et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Am J Hum Genet. 2019;104(4):651\u201364. \n                      https:\/\/doi.org\/10.1016\/j.ajhg.2019.02.017\n                      \n                    .","journal-title":"Am J Hum Genet"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1184-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T23:27:09Z","timestamp":1596065229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1184-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1184-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"31 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lauren Fishbein declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"104"}}